Larimar Therapeutics LRMR Income Statement (2013-2026)

NASDAQ LRMR
$3.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT
Reported Financials

Larimar Therapeutics Quarterly Income Statement

Periods 52 quarters
Latest Jun 2026

Larimar Therapeutics reported net income of -$32.80M for the quarter ended Jun 2026. This income statement covers 52 quarters of results from Jun 2013 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Operating items
Research & DevelopmentR&D
9.10M14.03M6.29M5.81M5.64M5.58M7.22M4.56M5.88M6.58M10.65M12.94M19.68M13.92M26.74M26.55M23.37M44.93M59.37M28.00M
Selling, General & AdministrativeSG&A
3.44M2.70M2.79M3.08M3.04M2.93M3.22M3.08M3.75M3.75M3.51M3.79M4.92M4.34M4.55M4.64M4.42M4.57M4.64M6.35M
Restructuring CostsRestructuring
Other Operating ExpensesOther Opex
Operating ExpensesOpex
12.54M16.73M9.09M8.89M8.69M8.51M10.44M7.64M9.62M10.34M14.16M16.73M24.60M18.26M31.29M31.19M27.79M49.50M64.02M34.35M
Operating IncomeOp. Inc
-12.54M-16.73M-9.09M-8.89M-8.69M-8.51M-10.44M-7.64M-9.62M-10.34M-14.16M-16.73M-24.60M-18.26M-31.29M-31.19M-27.79M-49.50M-64.02M-34.35M
EBIT
-12.54M-16.73M-9.09M-8.89M-8.69M-8.51M-10.44M-7.64M-9.62M-10.34M-14.16M-16.73M-24.60M-18.26M-31.29M-31.19M-27.79M-49.50M-64.02M-34.35M
Non-operating items
Non Operating Interest Expenses
Non Operating Investment IncomeNon-Op. Investment Inc.
Interest & Investment IncomeInt & Inv Inc
Other Non Operating IncomeOther Non Op Inc.
Non Operating IncomeNon Op. Inc.
-0.07M-0.07M-0.05M-0.06M0.02M0.19M1.01M1.11M1.25M1.27M1.17M2.08M2.97M2.77M2.47M1.91M1.61M1.79M1.52M1.57M
Net income details
EBT
-12.54M-16.73M-9.09M-8.89M-8.69M-8.51M-10.44M-7.64M-9.62M-10.34M-14.16M-16.73M-24.60M-18.26M-31.29M-31.19M-27.79M-49.50M-64.02M-34.35M
Profit After TaxPAT
-12.61M-16.81M-9.13M-8.94M-8.67M-8.32M-9.43M-6.53M-8.37M-9.07M-12.95M-14.65M-21.63M-15.50M-28.80M-29.28M-26.25M-47.71M-62.51M-32.80M
Income from Continuing OperationsIncome (Continuing)
-12.54M-16.73M-9.09M-8.89M-8.69M-8.51M-10.44M-7.64M-9.62M-10.34M-14.16M-16.73M-24.60M-18.26M-31.29M-31.19M-27.79M-49.50M-64.02M-34.35M
Consolidated Net IncomeConsol Net Inc.
-12.54M-16.73M-9.09M-8.89M-8.69M-8.51M-10.44M-7.64M-9.62M-10.34M-14.16M-16.73M-24.60M-18.26M-31.29M-31.19M-27.79M-49.50M-64.02M-34.35M
Income towards Parent CompanyParent Net Inc
-12.54M-16.73M-9.09M-8.89M-8.69M-8.51M-10.44M-7.64M-9.62M-10.34M-14.16M-16.73M-24.60M-18.26M-31.29M-31.19M-27.79M-49.50M-64.02M-34.35M
Preferred Dividend PaymentsPref Dividends
Net Income towards Common StockholdersNet Income
-12.54M-16.73M-9.09M-8.89M-8.69M-8.51M-10.44M-7.64M-9.62M-10.34M-14.16M-16.73M-24.60M-18.26M-31.29M-31.19M-27.79M-49.50M-64.02M-34.35M
Additional items
EPS (Basic)
-0.78-0.91-0.53-0.48-0.47-0.38-0.41-0.17-0.22-0.24-0.32-0.31-0.39-0.29-0.51-0.49-0.43-0.63-0.88-0.33
EPS (Diluted)
-0.78-0.91-0.53-0.48-0.47-0.38-0.41-0.17-0.22-0.24-0.32-0.31-0.39-0.29-0.51-0.49-0.43-0.63-0.87-0.33
Shares Outstanding
16.00M18.29M17.16M18.34M18.34M22.23M25.76M43.90M43.90M43.90M43.90M53.55M63.80M63.81M61.26M63.96M64.03M78.32M72.95M103.88M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
16.00M18.29M17.16M18.34M18.34M22.23M25.76M43.90M43.90M43.90M43.90M53.55M63.80M63.81M61.26M63.96M64.03M78.32M73.20M104.38M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
15.37M17.71M17.71M17.71M17.71M22.23M25.76M43.27M43.27M43.91M43.91M63.80M63.80M63.81M63.82M64.03M64.03M85.59M83.09M103.88M
EBITDA
-12.54M-16.73M-9.09M-8.89M-8.69M-8.51M-10.44M-7.64M-9.62M-10.34M-14.16M-16.73M-24.60M-18.26M-31.29M-31.19M-27.79M-49.50M-64.02M-34.35M
Interest ExpensesInt Expense